Table Info

Table 1.

Patient baseline characteristics

Cases	Primary disease	Sites of cancer at treatment initiation	Indication; treatment line	Treatment	Pre-existing comorbidities	Baseline medications
Case 1	Melanoma (resected stage 3A)	N/A	Adjuvant	Pembrolizumab, 6-weekly	Coeliac disease, osteoarthritis, hiatus hernia, rheumatoid arthritis	Nil
Case 2	Non-small cell lung cancer	Lung, bone, liver, leptomeningeal	Palliative; first-line	Pembrolizumab/Carboplatin/Pemetrexed, 3-weekly	high cholesterol, pulmonary embolus	Atorvastatin, apixaban, paracetamol, levetiracetam
Case 3	Renal cell carcinoma (clear cell)	Lung, bone	Palliative; third-line	Nivolumab, 4-weekly	Type 2 diabetes mellitus, spinal stenosis	Oramorph, zopiclone, lactulose

N/A: not applicable

Supplementary materials

The supplementary material for this article is available at: https://www.explorationpub.com/uploads/Article/file/1002250_sup_1.pdf.

Declarations

Author contributions

SG: Data curation, Investigation, Methodology, Visualization, Writing—original draft, Writing—review & editing. NS: Investigation, Visualization, Writing—review & editing. AOB: Conceptualization, Data curation, Methodology, Supervision, Writing—review & editing. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Cases were identified as part of a retrospective evaluation which had received regional approval (institution name: Clatterbridge Cancer Centre NHS Foundation Trust; registration number 2324-08).

Consent to participate

Informed consent to participate in the study was exempted by the local information governance officer, due to the completely anonymous nature of the information.

Consent to publication

Not applicable.

Availability of data and materials

Partial raw data (clinical records including documentation and imaging reports) for this manuscript are not publicly available because data contains personally identifiable information that may be restricted from public access to protect individuals’ privacy.

Funding

SG is a recipient of an NIHR Academic Clinical Fellowship. AOB is a holder of a UKRI ESRC [ES/W011484/1]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020;11:3801. [DOI] [PubMed] [PMC]

Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al.; CheckMate 816 Investigators. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022;386:1973–85. [DOI] [PubMed] [PMC]

Jin Y, Wei J, Weng Y, Feng J, Xu Z, Wang P, et al. Adjuvant Therapy With PD1/PDL1 Inhibitors for Human Cancers: A Systematic Review and Meta-Analysis. Front Oncol. 2022;12:732814. [DOI] [PubMed] [PMC]

Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, et al.; ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1217–38. [DOI] [PubMed]

Common terminology criteria for adverse events (CTCAE) version 5.0 [Internet]. Maryland: National Cancer Institute; [cited 2024 Apr 4]. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_50

Reynolds K, Thomas M, Dougan M. Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade. Oncologist. 2018;23:991–7. [DOI] [PubMed] [PMC]

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373:23–34. Erratum in: N Engl J Med. 2018;379:2185. [DOI] [PubMed] [PMC]

Pi B, Wang J, Tong Y, Yang Q, Lv F, Yu Y. Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management. Eur J Gastroenterol Hepatol. 2021;33:e858–67. [DOI] [PubMed] [PMC]

Intravenous N-acetylcysteine (NAC) for paracetamol overdose: reminder of authorised dose regimen; possible need for continued treatment with NAC [Internet]. Richmond: The National Archives Kew; [cited 2024 Apr 4]. Available from: https://www.gov.uk/drug-safety-update/intravenous-n-acetylcysteine-nac-for-paracetamol-overdose-reminder-of-authorised-dose-regimen-possible-need-for-continued-treatment-with-nac

10.

Berry P, Kotha S, Zen Y, Papa S, Menabawey TE, Webster G, et al. Immune checkpoint inhibitor-related cholangiopathy: Novel clinicopathological description of a multi-centre cohort. Liver Int. 2023;43:147–54. [DOI] [PubMed]

11.

Dougan M, Wang Y, Rubio-Tapia A, Lim JK. AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review. Gastroenterology. 2021;160:1384–93. [DOI] [PubMed]

12.

Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021;39:4073–126. Erratum in: J Clin Oncol. 2022;40:315. [DOI] [PubMed]

13.

Maurea S, Caleo O, Mollica C, Imbriaco M, Mainenti PP, Palumbo C, et al. Comparative diagnostic evaluation with MR cholangiopancreatography, ultrasonography and CT in patients with pancreatobiliary disease. Radiol Med. 2009;114:390–402. [DOI] [PubMed]

14.

Caruso M, Stanzione A, Prinster A, Pizzuti LM, Brunetti A, Maurea S, et al. Role of advanced imaging techniques in the evaluation of oncological therapies in patients with colorectal liver metastases. World J Gastroenterol. 2023;29:521–35. [DOI] [PubMed] [PMC]

15.

Caruso M, Romeo V, Stanzione A, Buonerba C, Di Lorenzo G, Maurea S. Current Imaging Evaluation of Tumor Response to Advanced Medical Treatment in Metastatic Renal-Cell Carcinoma: Clinical Implications. Appl Sci. 2021;11:6930. [DOI]